Kestra Advisory Services’s Amylyx Pharmaceuticals AMLX Stock Holding History

Kestra Advisory Services’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,936	Closed	-$478K	–	2055
2022 Q4	$478K	Sell	12,936 -29,747	-70%	-$1.06M	﹤0.01%	1437
2022 Q3	$1.2M	Buy	+42,683	New	+$1.06M	0.01%	887

Other funds holding AMLX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Kestra Advisory Services's AMLX Position: Q1 2023 in Review

Kestra Advisory Services sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2023, closing a stake of 12,936 shares — an estimated $478K sold.

Kestra Advisory Services first reported a position in AMLX in Q3 2022 and held it in 2 quarters. The position peaked at $1.2M in Q3 2022. 147 funds tracked by Wall St. Rank hold AMLX as of Q1 2023.

Kestra Advisory Services reported no remaining Amylyx Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Kestra Advisory Services sold 12,936 Amylyx Pharmaceuticals shares in Q1 2023, an estimated $478K.
Kestra Advisory Services first reported a position in Amylyx Pharmaceuticals in Q3 2022 and held it in 2 quarters.
Kestra Advisory Services's Amylyx Pharmaceuticals position peaked at $1.2M in Q3 2022.
147 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2023.

Based on Kestra Advisory Services's 13F filing for Q1 2023, filed 12 May 2023.